

DAFTAR PUSTAKA

1. Kulandaisamy PC, Kulandaisamy S, Kramer D, Mcgrath C. Malignant Pleural Effusions—A review of current guidelines and practices. *J Clin Med*. 2021;10(23):1-7.
2. Tian P, Qiu R, Wang M, Xu S, Cao L, Yang P *et al*. Prevalence, causes, and health care burden of pleural effusions among hospitalized adults in China. *JAMA Netw Open*. 2021;4(8):1-5.
3. Khairani R, Syahrudin E, Partakusuma LG. Karakteristik efusi pleura di rumah sakit persahabatan. *J Respir Indo*. 2012;32(3):155-60.
4. Dwianggita P. Etiologi efusi pleura pada pasien rawat inap di Rumah Sakit Umum Pusat Sanglah, Denpasar, Bali Tahun 2013. *Inti Sains Med*. 2016;7(1):57-66.
5. Rida Khairunnisa F. Karakteristik pasien dengan efusi pleura di bangsal paru RSUP M. Djamil Padang periode Januari 2017–Desember 2018 [skripsi]. Padang : Universitas Andalas; 2020.
6. Medford A, Maskell N. Pleural effusion. *Postgrad Med J*. 2005;81(961):702-10.
7. Fahmi Nofriandi F. Kadar interferon gamma (IFN- γ) cairan pleura pada efusi pleura tuberkulosis dan non-tuberkulosis [Tesis]. Padang : Universitas Andalas; 2016.
8. Na MJ. Diagnostic tools of pleural effusion. *Tuberc Respir Dis*. 2014;76(5):199-210.
9. Feller-Kopman D, Light R. A Pleural disease. *N Engl J Med*. 2018;378(8):740-51.
10. Froudarakis ME. Diagnostic work-up of pleural effusions. *Respiration*. 2008;75(1):4-13.
11. Mercer RM, Corcoran JP, Porcel JM, Rahman NM, Psallidas I. Interpreting pleural fluid results. *Clin Med*. 2019;19(3):213.
12. Beaudoin S, Gonzalez AV. Evaluation of the patient with pleural effusion. *CMAJ*. 2018;190(10):291-5.

13. Gouzy A, Nigou J, Gilleron M, Neyrolles O, Tailleux L, Gordon SV. Tuberculosis 2012: biology, pathogenesis and intervention strategies; an update from the city of light. *Res in Microbio.* 2013;164(3):270-80.
14. Valdés L, Alvarez D, San José E, Penela P, Valle JM, García-Pazos JM *et al.* Tuberculous pleurisy: a study of 254 patients. *Arch Intern Med.* 1998;158(18):2017-21.
15. Shimoda M, Hirata A, Tanaka Y, Morimoto K, Yoshiyama T, Yoshimori K *et al.* Characteristics of pleural effusion with a high adenosine deaminase level: a case-control study. *BMC Pulm Med.* 2022;22(359):1-10.
16. Maturu VN, Dhooria S, Bal A, Singh N, Aggarwal AN, Gupta D *et al.* Role of medical thoracoscopy and closed-blind pleural biopsy in undiagnosed exudative pleural effusions. *J Bronchol Intervent Pulmonol.* 2015;22(2):121-9.
17. Trapé J, Sant F, Franquesa J, Montesinos J, Arnau A, Sala M *et al.* Evaluation of two strategies for the interpretation of tumour markers in pleural effusions. *Respiratory Research.* 2017;18(1):1-8.
18. Prasenohadi, Nias NC, Putra AC, Harinda F, Nurwidya F. Cancer ratio diagnostic test for malignant pleural effusion patients treated at Persahabatan hospital Jakarta, Indonesia. *J Nat Sci Biol Med.* 2022;13(1):45-51.
19. Niu Y, Hu ZD. Diagnostic accuracy of pleural effusion biomarkers for malignant pleural mesothelioma: a machine learning analysis. *J Lab Precis Med.* 2021;6:1-5.
20. Solooki M, Miri M. Approach to undiagnosed exudative pleural effusion: the diagnostic yield of blind pleural biopsy. *Caspian J Intern Med.* 2013; 4(2):642-7.
21. Botana-Rial M, Vázquez-Iglesias L, Casado-Rey P, Cadena MP, Andrade-Olivié MA, Abal-Arca J *et al.* Validation of calprotectin as a novel biomarker for the diagnosis of pleural effusion: A multicentre trial. *Sci Rep.* 2020;10(1):1-8.

22. Sánchez-Otero N, Blanco-Prieto S, Páez de la Cadena M, Vázquez-Iglesias L, Fernández-Villar A, Botana-Rial MI *et al.* Calprotectin: a novel biomarker for the diagnosis of pleural effusion. *Br J Cancer.* 2012;107(11):1876-82.
23. Garcia V, Perera YR, Chazin WJ. A structural perspective on calprotectin as a ligand of receptors mediating inflammation and potential drug target. *Biomolecules.* 2022;12(4):1-14.
24. Antonangelo L, Faria CS, Sales RK. Tuberculous pleural effusion: diagnosis & management. *Expert Rev Respir Med.* 2019;13(8):747-59.
25. Scott NR, Swanson RV, Al-Hammadi N, Domingo-Gonzalez R, Rangel-Moreno J, Kriel BA *et al.* S100A8/A9 regulates CD11b expression and neutrophil recruitment during chronic tuberculosis. *J Clin Invest.* 2020;130(6):3098-112.
26. Kotsiou OS, Papagiannis D, Papadopoulou R, Gourgoulialis KI. Calprotectin in lung diseases. *Int J Mol Sci.* 2021;22(4):1-23.
27. Shabani F, Farasat A, Mahdavi M, Gheibi N. Calprotectin (S100A8/S100A9): a key protein between inflammation and cancer. *Inflamm Res.* 2018;67(10):801-12.
28. Srikrishna G. S100A8 and S100A9: new insights into their roles in malignancy. *J Innate Immun.* 2012;4(1):31-40.
29. Mohammed OM, Hussein KM, Ramadan AE, Mahmoud GT, El-Naggar ME, Gaber NE. Diagnostic value of calprotectin in differentiation between benign and malignant pleural effusion. *Egypt J Bronchol.* 2019;13:382-7.
30. Zocchi L. Physiology and pathophysiology of pleural fluid turnover. *Eur Respir J.* 2002;20(6):1545-58.
31. He T, Oh S. Diagnostic approach to pleural effusions. *AME Med J.* 2018;3(116):1-9.
32. Pratomo IP, Yunus F. Anatomi dan fisiologi pleura. *CDK.* 2013;40:407-12.
33. Jany B, Welte T. Pleural effusion in adults—etiology, diagnosis, and treatment. *Dtsch Arztebl Int.* 2019;116(21):377-86.
34. Karkhanis VS, Joshi JM. Pleural effusion: diagnosis, treatment, and management. *Open Access Emerg Med.* 2012;4:31-52.

35. Estenne M, Yernault JC, De Troyer A. Mechanism of relief of dyspnea after thoracentesis in patients with large pleural effusions. *Am J Med.* 1983;74(5):813-9.
36. Robers ME, Rahman NM, Maskell NA, Bibby AC, Blyth KG, Corcoran JP, Edey A *et al.* British thoracic society guideline for pleural disease. *Thorax.* 2023:1-34.
37. Pranita NP. Diagnosis dan tatalaksana terbaru penyakit pleura. *Wellness and Healthy Magz.* 2020;2(1):69-78.
38. Porcel JM. Pleural fluid biomarkers: beyond the Light criteria. *Clin Chest Med.* 2013;34(1):27-37.
39. Porcel JM. Biomarkers in the diagnosis of pleural diseases: a 2018 update. *The Adv Respir Dis.* 2018;12:1-11.
40. Bouros D, Pneumatikos I, Tzouveleki A. Pleural involvement in systemic autoimmune disorder. *Respiration.* 2008;75:361-71.
41. Jindal SK, Agarwal R. Upper respiratory tract tuberculosis. In: Schlossberg DL, editor. *Tuberculosis and nontuberculous mycobacterial infections.* Washington, DC: ASM Press; 2011. p. 247-265.
42. Trajman A, Pai M, Dheda K, vanZyl SR, Zwerling AA, Joshi R, Kalantri *et al.* Novel tests for diagnosing tuberculous pleural effusion: what works and what does not?. *Eur Respir J.* 2008;31(5):1098-106.
43. Aggarwal AN, Agarwal R, Sehgal IS, Dhooria S. Adenosine deaminase for diagnosis of tuberculous pleural effusion: A systematic review and meta-analysis. *PLoS One.* 2019;14(3):1-11.
44. Amalia RN, Pradjoko I. Nilai diagnostik adenosine deaminase (ADA) cairan pleura pada penderita efusi pleura tuberkulosis. *JR.* 2016;2(2):35-40.
45. Zhai K, Lu Y, Shi HZ. Tuberculous pleural effusion. *Jour Thorac Dis.* 2016;8(7):E486-E494.
46. Salmanzadeh S, Tavakkol H, Bavieh K, Alavi SM. Diagnostic value of serum adenosine deaminase (ADA) level for pulmonary tuberculosis. *Jundishapur J Microbiol.* 2015;8(3):1-5.

47. Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M *et al.* ERS/EACTS statement on the management of malignant pleural effusions. *Eur Respir J.* 2018;55(1):116-32.
48. Topolcan O, Holubec L, Polivkova V, Svobodova S, Pesek M, Treska V *et al.* Tumor markers in pleural effusions. *Anticancer Res.* 2007;27:1921-4.
49. Jukic A, Bakiri L, Wagner EF, Tilg H, Adolph TE. Calprotectin: from biomarker to biological function. *Gut.* 2021;70(10):1978-88.
50. Chen B, Miller AL, Rebelatto M, Brewah Y, Rowe DC, Clarke L *et al.* S100A9 induced inflammatory responses are mediated by distinct damage associated molecular patterns (DAMP) receptors in vitro and in vivo. *PloS One.* 2015;10(2):1-23.
51. Rochette L, Dogon G, Rigal E, Zeller M, Cottin Y, Vergely C. Involvement of oxidative stress in protective cardiac functions of calprotectin. *Cells.* 2022;11(7):1-12.
52. Narumi K, Miyakawa R, Ueda R, Hashimoto H, Yamamoto Y, Yoshida T *et al.* Proinflammatory proteins S100A8/S100A9 activate NK cells via interaction with RAGE. *J Immunol.* 2015;194(11):5539-48.
53. Shin YP. Age-related fecal calprotectin concentrations in healthy adults. *Korean J Clin Lab Sci.* 2020;52(3): 181-7.
54. Mortensen OH, Nielsen AR, Erikstrup C, Plomgaard P, Fischer CP, Krogh-Madsen R *et al.* Calprotectin—a novel marker of obesity. *PloS one.* 2009;4(10):1-4.
55. Soeters PB, Wolfe RR, Shenkin A. Hypoalbuminemia: pathogenesis and clinical significance. *JPEN J Parenter Enteral Nutr.* 2019;43(2):181-93.
56. Gopal R, Monin L, Torres D, Slight S, Mehra S, McKenna KC *et al.* S100A8/A9 proteins mediate neutrophilic inflammation and lung pathology during tuberculosis. *Am J respir Crit Care Med.* 2013;188(9):1-57.
57. Wang S, Song R, Wang Z, Jing Z, Wang S, Ma J. S100A8/A9 in Inflammation. *Front Immunol.* 2018;9:1-14.
58. Silva EJ, Argyris PP, Zou X, Ross KF, Herzberg MC. S100A8/A9 regulates MMP-2 expression and invasion and migration by carcinoma cells. *Int J Biochem Cell Biol.* 2014;55:279-87.

59. Miao P, Sheng S, Sun X, Liu J, Huang G. Lactate dehydrogenase A in cancer: a promising target for diagnosis and therapy. *IUBMB life*. 2013;65(11):904-10.
60. Valdés L, San-José E, Ferreiro L, Golpe A, González-Barcala FJ, Toubes ME *et al*. Predicting malignant and tuberculous pleural effusions through demographics and pleural fluid analysis of patients. *Clin Respir J*. 2015;9(2):203-13.
61. Gupta R, Gupta A, Ilyas M. Spectrum of pleural effusion etiology revisited in 18–70 years of age group: A tertiary care center-based study of 1000 patients. *CHRISMED J Health Res*. 2018;5(2):110-3.
62. Darooei R, Sanadgol G, Gh-Nataj A, Almasnia M, Darivishi A, Eslaminejad A *et al*. Discriminating tuberculous pleural effusion from malignant pleural effusion based on routine pleural fluid biomarkers, using mathematical methods. *Tanaffos*. 2017;16(2):157-165.
63. Schwalk AJ, Ost DE, Saltijeral SN, De La Garza H, Casal RF, Jimenez CA *et al*. Risk factors for and time to recurrence of symptomatic malignant pleural effusion in patients with metastatic non-small cell lung cancer with EGFR or ALK mutations. *Chest*. 2021;159(3):1256-64.
64. Chen KY, Feng PH, Chang CC, Chen TT, Chuang HC, Lee CN *et al*. Novel biomarker analysis of pleural effusion enhances differentiation of tuberculous from malignant pleural effusion. *Int J Gen Med*. 2016:183-9.
65. Kim HW, Kim KH, Shin AY, Choi JY, Ahn JH, Kim JS *et al*. Investigating the appropriate adenosine deaminase cutoff value for the diagnosis of tuberculous pleural effusion in a country with decreasing TB burden. *Sci Rep*. 2022;12(1):1-13.
66. Park HJ, Cho JH, Kim HJ, Park JY, Lee HS, Byun MK. The effect of low body mass index on the development of chronic obstructive pulmonary disease and mortality. *J Intern Med*. 2019;286(5):573-82.
67. Gao L, Wang W, Zhang Y, Hu X, An J, Li Y *et al*. Adenosine deaminase-based measurement in the differential diagnosis of pleural effusion: a multicenter retrospective study. *Ther Adv Respir Dis*. 2023;17:1-11.

68. Reddy SL, Varaprasad K, Narahari N, Bhaskar K, Varma GR, Paramjyothi GK. Clinical and etiological profile of an exudative pleural effusion in a tertiary care center. *Indian J Respir Care*. 2019;8(1):22-26.
69. McNally E, Ross C, Gleeson LE. The tuberculous pleural effusion. *Breathe*. 2023;19(4):1-14.
70. Verma A, Dagaonkar RS, Marshall D, Abisheganaden J, Light RW. Differentiating malignant from tubercular pleural effusion by cancer ratio plus (cancer ratio: pleural lymphocyte count). *Can Respir J*. 2016;2016:1-6.
71. Ramadhan Ananda P. Perbedaan Kadar Neuron Spesifik Enolase Cairan Pleura dan Cancer Ratio antara Efusi Pleura Maligna dengan Efusi Pleura Tuberkulosis [Tesis]. Padang : Universitas Andalas; 2022.
72. Alkhatib AJ, Alrakaf NA. Lactate dehydrogenase: physiological roles and clinical implications. *Clin Med*. 2019;137(5):363-9.
73. Wang J, Feng ZX, Ren T, Meng WY, Khan I, Fan XX *et al*. Novel clinical biomarkers in blood and pleural effusion for diagnosing patients with tuberculosis distinguishing from malignant tumor. *Medicine*. 2022;101(41):1-10.
74. Cascio CM, Kaul V, Dhooria S, Agrawal A, Chaddha U. Diagnosis of tuberculous pleural effusions: A review. *Respir Med*. 2021;188:1-8.
75. Jovanovic D. Etiopathogenesis of malignant pleural effusion. *AME Med J*. 2021;6:1-7.
76. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin*. 2019;69(1):7-34.
77. Hardavella G, Karampinis I. Primary lung cancer and pleural effusion—diagnostic and therapeutic approach. *AME Med J*. 2020;5:1-8.
78. Patel AB, Patel AJ, Shah VD, Patel MB. Diagnostic Evaluation Of 120 Cases Of Pleural Effusion In A Tertiary Care Center In Ahmedabad, India. *BJMHS*. 2020;2(5):211-14.
79. Wang XJ, Yang Y, Wang Z, Xu LL, Wu YB, Zhang J *et al*. Efficacy and safety of diagnostic thoracoscopy in undiagnosed pleural effusions. *Respiration*. 2015;90(3):251-5.

Munn LL. Cancer and inflammation. Wiley Interdiscip Rev Syst Biol Med.2016;9(2):1-13.

